Stock 2096 SIMCERE PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Simcere Pharmaceutical Group Limited

Equities

2096

HK0000658531

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:06 2024-04-30 am EDT 		5-day change 1st Jan Change
5.4 HKD -.--% Intraday chart for Simcere Pharmaceutical Group Limited +3.65% -19.76%
Apr. 25 Simcere Pharmaceutical’ Profit Down 23% in 2023 MT
Apr. 10 Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Simcere Pharmaceutical’ Profit Down 23% in 2023
MT
Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA
MT
Simcere Pharmaceutical Group Limited Announces SIM0500 for Injection (a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody) Receives Fast Track Designation by the U.S. Food and Drug Administration
CI
Simcere Pharmaceutical's 2023 Profit Falls, Misses Estimates; Shares Rise 3%
MT
Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024
CI
Simcere Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Simcere Pharmaceutical Group's Cancer Drug NDA Accepted by Chinese Regulator
MT
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China
CI
Simcere Pharmaceutical Group's Cancer Drug Gets China Nod for Clinical Trials
MT
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration
CI
Simcere Pharmaceutical Group's New Anti-Cancer Drug Gets Clinical Trials Approval from the FDA
MT
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500
CI
Simcere Pharmaceutical Group Limited Announces Findings of A Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in Jama
CI
Simcere Pharma's Ischemic Stroke Treatment Results Published in US Neurology Journal
MT
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023
MT
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%
MT
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023
CI
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19
CI
Simcere Pharma Unit's Shareholders Approve Order Collection Agreement
MT
China Grants Clinical Trial Approval for Simcere Pharmaceutical's Anti-Tumor Medication
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2096 Stock
  4. News Simcere Pharmaceutical Group Limited